A new study in liver cancer describes how Nrf2—known as a metabolic master regulator—helps drive accumulation of regulatory T cells (Tregs) in hepatocellular carcinoma. By linking metabolic signaling to immune evasion, the work points to potential therapeutic strategies that combine metabolic pathway targeting with approaches designed to relieve immunosuppression in the tumor microenvironment. The findings broaden the mechanistic map for hepatocellular carcinoma immune resistance and provide a more actionable set of targets for drug developers working on the intersection of tumor metabolism and adaptive immune modulation.